The Global Intestinal Fistula Treatment Industry is set to reach unprecedented heights, with a projected valuation of US$ 46.82 Billion by 2033, showcasing a remarkable Compound Annual Growth Rate (CAGR) of 5.8%. This surge is attributed to continuous advancements in drugs and biotechnology, paving the way for trans.